Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its participation in an upcoming virtual fireside chat. CEO Marcio Souza will engage in a discussion with Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00am EST. The company specializes in developing treatments targeting neuronal excitation-inhibition imbalance in CNS disorders.
Positive
- None.
Negative
- None.
News Market Reaction 10 Alerts
On the day this news was published, PRAX gained 1.69%, reflecting a mild positive market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $16M to the company's valuation, bringing the market cap to $966M at that time.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST.
The event will be webcast live and the registration link can be found here.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
When is the Praxis Precision Medicines (PRAX) fireside chat with Piper Sandler?
Who will represent Praxis Precision Medicines at the Piper Sandler fireside chat?
What type of company is Praxis Precision Medicines (PRAX)?
How can investors access the Praxis Precision Medicines fireside chat?
